MACROPLASTIQUE IMPLANTS MPQ-2.5

MAUDE Adverse Event Report

MAUDE data represents reports of adverse events involving medical devices. This maude entry was filed with the FDA on 2019-04-25 for MACROPLASTIQUE IMPLANTS MPQ-2.5 manufactured by Uroplasty, Llc.

Event Text Entries

[145648746] Macroplastique implants are not indicated for treatment of vur within the united states (only female sui), however the vur indication exists for all geographies outside of the us. This event is being conservatively reported to fda as a) it was unclear based on the content of the published case study whether or not the macroplastique was removed at the time of bladder stone removal and b) due to the fact that treatment with mpq for vur is similar to that for sui and therefore this type of event has the potential to occur within the us.
Patient Sequence No: 1, Text Type: N, H10


[145648747] This event was discovered during a literature search related to macroplastique (mpq) for treatment of vesicoureteral reflux (vur) and was found in the form of a case study. A (b)(6) male patient had undergone treatment with mpq when he was 9 months of age after being diagnosed with unilateral grade v vur. The patient presented with intermittent gross hematuria and supra-pubic pain for several months. The patient was treated with antibiotics for suspected cystitis and the symptoms disappeared within several days. Two years after the mpq injection, the patient presented with gross hematuria (four times) and microscopic hematuria (two times). Whenever hematuria was present, the patient's urine calcium/creatinine ratio was checked and results were normal. Urinalysis showed isomorphic hematuria and mild proteinuria. A ct scan was performed and showed two 0. 7 cm hyperdense lesions in the left posterior aspects of the bladder and suspected stones at the uvj or in the bladder. Ultrasonography showed previous mild pelvirectal of the left kidney (0. 3 cm) and two hyperechoic foci with posterior acoustic shadowing in the left posterior aspect of the bladder. A diagnostic cystoscopy was performed showing calcifications leading to mucosal erosions around the orifice where mpq had been previously injected. The calcifications on the mucosal area were successfully removed via laser, however it is unclear if any mpq was also removed at this time. The patient's symptoms were gradually relived after treatment and routine monitoring for seven months after the removal of the calcifications showed no recurrent symptoms.
Patient Sequence No: 1, Text Type: D, B5


MAUDE Entry Details

Report Number3002647932-2019-00002
MDR Report Key8548960
Date Received2019-04-25
Date of Report2019-04-19
Date Mfgr Received2019-03-28
Date Added to Maude2019-04-25
Event Key0
Report Source CodeManufacturer report
Manufacturer LinkY
Number of Patients in Event0
Adverse Event Flag3
Product Problem Flag3
Reprocessed and Reused Flag3
Health Professional3
Initial Report to FDA3
Report to FDA3
Event Location3
Manufacturer ContactMS. NICOLE BOSER
Manufacturer Street5420 FELTL ROAD
Manufacturer CityMINNETONKA MN 55343
Manufacturer CountryUS
Manufacturer Postal55343
Manufacturer Phone9524266141
Manufacturer G1UROPLASTY, LLC
Manufacturer Street5420 FELTL ROAD
Manufacturer CityMINNETONKA MN 55343
Manufacturer CountryUS
Manufacturer Postal Code55343
Single Use3
Previous Use Code3
Event Type3
Type of Report0

Device Details

Brand NameMACROPLASTIQUE IMPLANTS
Generic NameAGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE
Product CodeLNM
Date Received2019-04-25
Model NumberMPQ-2.5
Catalog NumberMPQ-2.5
OperatorHEALTH PROFESSIONAL
Device AvailabilityN
Device Eval'ed by MfgrR
Device Sequence No1
Device Event Key0
ManufacturerUROPLASTY, LLC
Manufacturer Address5420 FELTL ROAD MINNETONKA MN 55343 US 55343


Patients

Patient NumberTreatmentOutcomeDate
101. Required No Informationntervention 2019-04-25

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.